Discover
KALV
KalVista Pharmaceuticals Inc
27.00
2 x 19.43
2 x 34.54
bid
ask
+
27.00
0.00%
2 @ 04:00 PM
26.99 -0.01 (0.04%)
| Ytd | 67.18% | |
| 1y | 106.26% |
26.98
day range
27.00
9.83
52 week range
27.00
| Open | 26.99 | Prev Close | Low | 26.98 | High | 27.00 | Mkt Cap | 1.44B | |
| Vol | 4.26M | Avg Vol | 3.63M | EPS | -3.94 | P/E | N/A | Forward P/E | 15.82 |
| Beta | -0.11 | Short Ratio | 0.94 | Inst. Own | 136.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 24.43 | 200-d Avg | 17.09 | 1yr Est | 27.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-03-24 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-12-04 | 2025-10 | 0 | N/A | N/A | N/A |
| 2025-11-10 | 2025-09 | 0 | N/A | 0.04 | 4.17% |
| 2025-09-11 | 2025-07 | 0 | N/A | -0.21 | -23.08% |
| 2025-07-10 | 2025-04 | 0 | N/A | -0.22 | -28.57% |
| 2025-03-12 | 2025-01 | 0 | N/A | -0.03 | -3.37% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-01 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-04-30 | Needham | Downgrade | Buy | Hold |
| 2026-03-26 | Stifel | Upgrade | Buy | Buy |
| 2026-03-26 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-03-25 | Needham | Upgrade | Buy | Buy |
| 2026-01-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-25 | AUDHYA PAUL K | Officer | 150.26K | Sale |
| 2026-05-21 | PALLEIKO BENJAMIN L | Chief Executive Officer | 479.99K | Sale |
| 2026-05-21 | PIEKOS BRIAN | Chief Financial Officer | 21.66K | Sale |
| 2026-05-25 | SWEENY NICOLE | Officer | 59.29K | Sale |
| 2026-03-25 | VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-05-26 | YEA CHRISTOPHER M | Officer | 229.92K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Venrock Adviser, LLC | 6.47M | 174.81M | 12.16% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 4.96M | 133.95M | 9.32% |
| 2026-03-30 | Suvretta Capital Management, LLC | 4.77M | 128.76M | 8.96% |
| 2026-03-30 | Tang Capital Management, LLC | 4.57M | 123.49M | 8.59% |
| 2026-03-30 | Blackrock Inc. | 3.80M | 102.49M | 7.13% |
| 2026-03-30 | SilverArc Capital Management, LLC | 2.88M | 77.66M | 5.40% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 2.81M | 75.83M | 5.28% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.35M | 36.45M | 2.54% |
| 2026-04-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.20M | 32.53M | 2.26% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 905.84K | 24.46M | 1.70% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 439.45K | 11.87M | 0.83% |
| 2026-02-27 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 375.71K | 10.14M | 0.71% |
Split
| Split | Date |
|---|---|
| 1 : 14 | 2016-11-22 |
| 1 : 14 | 2016-11-21 |